Albertans living with ALS, commonly referred to as Lou Gehrig’s Disease, have a new treatment option that can improve their quality of life and help them live longer — one the Alberta government will cover for the estimated $18,500 a month per patient.
On Aug. 1, the province added the trademark drug, Albrioza, to the Alberta Drug Benefit List, which allows eligible patients to be reimbursed for the cost of the treatment.
Alberta joins Ontario, Quebec, British Columbia and New Brunswick to provide public coverage for the drug.
It’s more than a year after Health Canada conditionally approved the drug in June 2022.
Leslie Ring-Adams, executive director
